P18:来自诱导瘤抑制细胞的新型抗癌,准乳腺癌和骨转移
Changpeng Cui1,2, Qingji Huo1,2, Xue Xiong1,2
1Department of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin 150081, China.
Cancers
|June 27, 2024
概括
研究人员从瘤抑制细胞中鉴定出P18,一种新的抗癌 (ACP). 通过准GTPase信号通路,P18有效地抑制乳腺癌的生长,转移和骨破坏.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 乳腺癌经常转移到骨系统.
- 诱导性瘤抑制细胞 (iTSCs) 分泌瘤抑制蛋白质.
- 这项研究探讨了从iTSC衍生的蛋白质碎片中识别抗癌 (ACP).
研究的目的:
- 来自诱导瘤抑制细胞 (iTSCs) 的新型抗癌 (ACPs) 的识别和特征.
- 评估已识别的ACP对乳腺癌和骨转移的治疗潜力.
- 为了阐明基底的分子机制,ACP中介的抗癌效应.
主要方法:
- 类库的选和表征. 类库的选和表征.
- 在体外测试:细胞活力,运动性,增殖和侵入性.
- 在体内测试:ex vivo癌症组织和骨微环境模型.
- 机制研究:GTPase活性测定和分子对接.
主要成果:
- 来自Arhgdia的P18对乳腺癌细胞表现出强大的抗癌活性.
- P18抑制了癌细胞的活力,迁移,入侵和Rho GTPase信号传递 (RhoA,Cdc42).
- 通过抑制骨质细胞成熟,P18减轻了乳腺癌引起的骨损失,并与化疗显示出协同效应.
结论:
- 建立了一种新的方法,用于从iTSC秘密体中发现ACP.
- P18是乳腺癌治疗和骨转移预防的有前途的治疗候选药物.
- 准GTPase信号传递是乳腺癌治疗的可行策略.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
510
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


